{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"OABI","limit":50},"count":50,"signals":[{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":100,"match_count":69,"context":"difficult to attract new partners. Our partners failure to effectively advance, market and sell suitable therapeutic candidates with the antibodies that are discovered using our platform could have a material adverse effect on our business, financial condition, results of operations and prospects, and cause the market price of our common stock to decline. In addition to the inherent uncertainty in drug development addre","filed_date":"2026-03-04","accession":"0001846253-26-000009","full_text":"https://origin.rootz.global/static/filing/0001846253-26-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":100,"match_count":40,"context":"RS  The proposal regarding the election of directors requires the approval of a plurality of the votes cast. This means that the nominees receiving the highest number of affirmative FOR votes will be elected as Class III Directors. Votes withheld and broker non-votes are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal.  | | | | | | OUR BOARD OF DIRECTORS UNANIM","filed_date":"2025-04-29","accession":"0001846253-25-000042","full_text":"https://origin.rootz.global/static/filing/0001846253-25-000042.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":100,"match_count":68,"context":"difficult to attract new partners. Our partners failure to effectively advance, market and sell suitable therapeutic candidates with the antibodies that are discovered using our platform could have a material adverse effect on our business, financial condition, results of operations and prospects, and cause the market price of our common stock to decline. In addition to the inherent uncertainty in drug development addre","filed_date":"2025-03-18","accession":"0001846253-25-000024","full_text":"https://origin.rootz.global/static/filing/0001846253-25-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":100,"match_count":43,"context":"RS  The proposal regarding the election of directors requires the approval of a plurality of the votes cast. This means that the nominees receiving the highest number of affirmative FOR votes will be elected as Class II Directors. Votes withheld and broker non-votes are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal.  | | | | | | | | | | | | | | | | | | | | |","filed_date":"2024-04-26","accession":"0001846253-24-000023","full_text":"https://origin.rootz.global/static/filing/0001846253-24-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":100,"match_count":69,"context":"erapeutic candidates generated using our platform. Any disclosure by us or our partners of data or other information regarding any such therapeutic candidates that is perceived as negative may have a material adverse impact on our stock price or overall valuation. Our stock price may also decline as a result of negative clinical trial results, including adverse safety events involving any drug candidate that is subject","filed_date":"2024-03-25","accession":"0001846253-24-000006","full_text":"https://origin.rootz.global/static/filing/0001846253-24-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":100,"match_count":57,"context":"RS  The proposal regarding the election of directors requires the approval of a plurality of the votes cast. This means that the nominees receiving the highest number of affirmative FOR votes will be elected as Class I Directors. Votes withheld and broker non-votes are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal.  | | | | | | | | | | | | | | | | | | | | |","filed_date":"2023-05-01","accession":"0001846253-23-000055","full_text":"https://origin.rootz.global/static/filing/0001846253-23-000055.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":100,"match_count":40,"context":"erapeutic candidates generated using our platform. Any disclosure by us or our partners of data or other information regarding any such therapeutic candidates that is perceived as negative may have a material adverse impact on our stock price or overall valuation. Our stock price may also decline as a result of negative clinical trial results, including adverse safety events involving any drug candidate that is subject","filed_date":"2023-03-30","accession":"0001846253-23-000026","full_text":"https://origin.rootz.global/static/filing/0001846253-23-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"CA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Courts decision, President Biden issued an Executive Order to initiate a special enrollment period from February15, 2021 through August15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agenci","filed_date":"2023-02-07","accession":"0001193125-23-025909","full_text":"https://origin.rootz.global/static/filing/0001193125-23-025909.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":100,"match_count":40,"context":"erapeutic candidates generated using our platform. Any disclosure by us or our partners of data or other information regarding any such therapeutic candidates that is perceived as negative may have a material adverse impact on our stock price or overall valuation. Our stock price may also decline as a result of negative clinical trial results, including adverse safety events involving any drug candidate that is subject","filed_date":"2023-02-07","accession":"0001193125-23-025909","full_text":"https://origin.rootz.global/static/filing/0001193125-23-025909.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":100,"match_count":72,"context":".  Immediately prior to the Distribution and Business Combination, Legacy OmniAb was a wholly-owned subsidiary of Ligand and each of the individuals named in the Summary Compensation Table below (our named executive officers) were employed by Ligand or its subsidiaries. Accordingly, all pre-Distribution payments and benefits described below were provided by Ligand and decisions regarding past compensation of our named e","filed_date":"2023-02-07","accession":"0001193125-23-025909","full_text":"https://origin.rootz.global/static/filing/0001193125-23-025909.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"CA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Courts decision, President Biden issued an Executive Order to initiate a special enrollment period from February15, 2021 through August15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agenci","filed_date":"2022-11-30","accession":"0001193125-22-295453","full_text":"https://origin.rootz.global/static/filing/0001193125-22-295453.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":100,"match_count":40,"context":"erapeutic candidates generated using our platform. Any disclosure by us or our partners of data or other information regarding any such therapeutic candidates that is perceived as negative may have a material adverse impact on our stock price or overall valuation. Our stock price may also decline as a result of negative clinical trial results, including adverse safety events involving any drug candidate that is subject","filed_date":"2022-11-30","accession":"0001193125-22-295453","full_text":"https://origin.rootz.global/static/filing/0001193125-22-295453.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":100,"match_count":65,"context":"ive affiliates, prior to completion of the Business Combination.  Immediately prior to the Distribution and Business Combination, Legacy OmniAb was a wholly-owned subsidiary of Ligand and each of the named executive officers identified below was employed by Ligand or one of its subsidiaries. Accordingly, all pre-Distribution payments and benefits described below were provided by Ligand. For purposes of this registration","filed_date":"2022-11-30","accession":"0001193125-22-295453","full_text":"https://origin.rootz.global/static/filing/0001193125-22-295453.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":100,"match_count":14,"context":"initial Business Combination with only a single entity, our lack of diversification may: | | | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial Business Combination; and | | | | | cause us to depend on the marketing and sale of a single product or limited number of products or","filed_date":"2022-03-28","accession":"0001104659-22-038205","full_text":"https://origin.rootz.global/static/filing/0001104659-22-038205.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":100,"match_count":57,"context":"ure Schedule delivered by the Company to Parent on the date hereof and identified as such. (26) Company Equity Award has the meaning given to such term in the Employee Matters Agreement. (27) Company Material Adverse Effect means any Effect that has, or would reasonably be expected to, individually or in the aggregate, materially impair, materially delay or otherwise have a material adverse effect on the ability of the","filed_date":"2022-03-24","accession":"0001104659-22-037314","full_text":"https://origin.rootz.global/static/filing/0001104659-22-037314.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":100,"match_count":14,"context":"oration. Section 2.5 Governance Matters. (a) The Parties shall use reasonable best efforts to ensure that the individuals listed on Section 2.5(a) of the Company Disclosure Schedule are nominated and elected as directors of Parent effective immediately after the Closing, and the identities of such individuals shall be made publicly available as promptly as practicable following the date hereof (but in any event prio","filed_date":"2022-03-24","accession":"0001104659-22-037314","full_text":"https://origin.rootz.global/static/filing/0001104659-22-037314.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_concentration","strength":98,"match_count":1,"context":"have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business.  In recent periods, a limited number of partners accounted for a significant portion of our revenue. For the nine months ended September30, 2022 and the year ended December31, 2021, three of our partners accounted for 29%, 20% and 13% and 28%, 24% and 11%, respectively, of our revenue, and 33 and 2","filed_date":"2023-02-07","accession":"0001193125-23-025909","full_text":"https://origin.rootz.global/static/filing/0001193125-23-025909.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_concentration","strength":98,"match_count":1,"context":"have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business.  In recent periods, a limited number of partners accounted for a significant portion of our revenue. For the nine months ended September30, 2022 and the year ended December31, 2021, three of our partners accounted for 29%, 20% and 13% and 28%, 24% and 11%, respectively, of our revenue, and 33 and 2","filed_date":"2022-11-30","accession":"0001193125-22-295453","full_text":"https://origin.rootz.global/static/filing/0001193125-22-295453.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"the executive officer only if the market price of the shares appreciates over the option term.  Time-based restricted stock units granted to the named executive officers generally vest in equal installments over three years.  No performance stock units have been granted by OmniAb to the named executive officers to date.  The HCMCC views granting equity awards as a retention device and therefore also","filed_date":"2025-04-29","accession":"0001846253-25-000042","full_text":"https://origin.rootz.global/static/filing/0001846253-25-000042.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"the executive officer only if the market price of the shares appreciates over the option term.  Time-based restricted stock units granted to the named executive officers generally vest in equal installments over three years.  No performance stock units have been granted by OmniAb to the named executive officers to date.  | | | | | | | | | 32 | 2024 PROXY STATEMENT | | | | | | | | NARRATIVE DISCLOSUR","filed_date":"2024-04-26","accession":"0001846253-24-000023","full_text":"https://origin.rootz.global/static/filing/0001846253-24-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"tive officer only if the market price of the shares appreciates over the option term.  Time-based restricted stock units granted by Ligand to the named executive officers generally vest in equal installments over three years.  Performance stock units granted by Ligand to the named executive officers were a significant component of Ligands annual long-term equity incentive awards for the executive off","filed_date":"2023-05-01","accession":"0001846253-23-000055","full_text":"https://origin.rootz.global/static/filing/0001846253-23-000055.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_concentration","strength":88,"match_count":1,"context":"e have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business. In recent periods, a limited number of partners accounted for a significant portion of our revenue. For the years ended December31, 2022 and 2021, three of our partners accounted for 72% and 63% respectively, of our revenue, and 36 and 26 partners accounted for the remaining 28% and 37%, respectiv","filed_date":"2023-03-30","accession":"0001846253-23-000026","full_text":"https://origin.rootz.global/static/filing/0001846253-23-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_concentration","strength":78,"match_count":1,"context":"e have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business. In recent periods, a limited number of partners accounted for a significant portion of our revenue. For the years ended December31, 2025 and 2024, three of our partners accounted for 37% and 35% respectively, of our revenue, and 27 and 30 partners accounted for the remaining 63% and 65%, respectiv","filed_date":"2026-03-04","accession":"0001846253-26-000009","full_text":"https://origin.rootz.global/static/filing/0001846253-26-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_concentration","strength":78,"match_count":1,"context":"e have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business. In recent periods, a limited number of partners accounted for a significant portion of our revenue. For the years ended December31, 2024 and 2023, three of our partners accounted for 48% and 58% respectively, of our revenue, and 30 and 33 partners accounted for the remaining 52% and 42%, respectiv","filed_date":"2025-03-18","accession":"0001846253-25-000024","full_text":"https://origin.rootz.global/static/filing/0001846253-25-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_concentration","strength":73,"match_count":1,"context":"e have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business. In recent periods, a limited number of partners accounted for a significant portion of our revenue. For the years ended December31, 2023 and 2022, three of our partners accounted for 58% and 72% respectively, of our revenue, and 33 and 36 partners accounted for the remaining 42% and 28%, respectiv","filed_date":"2024-03-25","accession":"0001846253-24-000006","full_text":"https://origin.rootz.global/static/filing/0001846253-24-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":72,"match_count":9,"context":"tation and agreement (in the form provided by  8 the Corporation within ten (10) days upon written request of any stockholder of record therefor) that such candidate for nomination (A) is not and, if elected as a director during his or her term of office, will not become a party to (1) any agreement, arrangement or understanding with, and has not given and will not give any commitment or assurance to, any person or en","filed_date":"2026-01-30","accession":"0001846253-26-000002","full_text":"https://origin.rootz.global/static/filing/0001846253-26-000002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":56,"match_count":7,"context":"if any Award, compensation or other benefits under the Plan are determined to constitute noncompliant nonqualified deferred compensation subject to taxes, penalties or interest under Section 409A. (b)Separation from Service. If an Award constitutes nonqualified deferred compensation under Section 409A, any payment or settlement of such Award upon a termination of a Participants Service Provider relationship will","filed_date":"2022-10-24","accession":"0001104659-22-110957","full_text":"https://origin.rootz.global/static/filing/0001104659-22-110957.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":56,"match_count":7,"context":"e diligence. Our officers have agreed not to become an officer or director of any other special purpose acquisition company with a class of securities registered under the Exchange Act, until we have entered into a definitive agreement regarding our initial Business Combination or we have failed to complete a Business Combination within 18 months from the IPO Closing Date. Our officers and  9 [Table of Contents](#TOC) directors wou","filed_date":"2022-03-28","accession":"0001104659-22-038205","full_text":"https://origin.rootz.global/static/filing/0001104659-22-038205.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"growth_inflection","strength":40,"match_count":5,"context":"revenue |  |  $ |  23,732 |  |  |  $ |  19,468 |  |  |  $ |  4,264 |  |  |  |  22 |  % | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | |  (1) |  percentage change is not meaningful | | Total revenue increased $0.6million, or 10%, in the three months ended September30, 2022 as compared to 2021 driven primarily by royalty revenue from our partners sales of zimberelimab and sugemalimab.  Total revenue increased $4.3mill","filed_date":"2023-02-07","accession":"0001193125-23-025909","full_text":"https://origin.rootz.global/static/filing/0001193125-23-025909.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"tion8.1Conditions to the Obligations of SpinCo, the Company, Parent and Merger Sub to Effect the Merger. The respective obligations of each Party to consummate the Merger shall be subject to the fulfillment (or, to the extent permitted by applicable Law, waiver by the Company and Parent) at or prior to the Closing of the following conditions: (a)(i)the waiting period (or any extension thereof) under","filed_date":"2022-03-24","accession":"0001104659-22-037314","full_text":"https://origin.rootz.global/static/filing/0001104659-22-037314.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"restructuring","strength":37,"match_count":4,"context":"and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported in the consolidated statements of comprehensive income (loss). Restructuring Costs 87 [Table of Contents](#i6f791f60b359483baae337662e2023d2_7) Restructuring costs relate to cost realignment actions implemented in February and July of 2025 by the Company to optimize business operat","filed_date":"2026-03-04","accession":"0001846253-26-000009","full_text":"https://origin.rootz.global/static/filing/0001846253-26-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":34,"match_count":3,"context":"rially from those in this Quarterly Report are any of the risks described in our Annual Report on Form 10-K filed with the SEC on March 28, 2022. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As o","filed_date":"2022-05-20","accession":"0001104659-22-063431","full_text":"https://origin.rootz.global/static/filing/0001104659-22-063431.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"came into force in December 2024, to be implemented into EU member state national law by December 2026. This Directive extends the EUs existing strict product liability regime to AI Technologies and AI-enabled products, and facilitates civil claims in respect of harm caused by AI. Once fully applicable, the EU AI Act and the EU Product Liability Directive will have a material impact on the way AI is regulated in t","filed_date":"2026-03-04","accession":"0001846253-26-000009","full_text":"https://origin.rootz.global/static/filing/0001846253-26-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"uropean Commission proposed two Directives seeking to establish a harmonized civil liability regime for AI in the EU in order to facilitate civil claims in respect of harm caused by AI and to include AI-enabled products within the scope of the EUs existing strict product liability regime. Once fully applicable, the EU AI Act and the Liability Directives will have a material impact on the way AI is regulated in the","filed_date":"2025-03-18","accession":"0001846253-25-000024","full_text":"https://origin.rootz.global/static/filing/0001846253-25-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"growth_inflection","strength":32,"match_count":4,"context":"venue |  |  $ |  23,732 |  |  |  $ |  19,468 |  |  |  $ |  4,264 |  |  |  |  22 |  % | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | |  (1) |  percentage change is not meaningful | | Total revenue increased $0.6million, or 10%, in the three months ended September30, 2022 as compared to 2021 driven primarily by royalty revenue from our partners sales of zimberelimab and sugemalimab.  Total revenue increased $4.3mill","filed_date":"2022-11-30","accession":"0001193125-22-295453","full_text":"https://origin.rootz.global/static/filing/0001193125-22-295453.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":32,"match_count":4,"context":"vatives and Hedging -- Contracts in Entitys Own Equity (Subtopic 815-40) (ASU 2020-06) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entitys o","filed_date":"2022-01-12","accession":"0001104659-22-003279","full_text":"https://origin.rootz.global/static/filing/0001104659-22-003279.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":32,"match_count":4,"context":"vatives and Hedging -- Contracts in Entitys Own Equity (Subtopic 815-40) (ASU 2020-06) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entitys o","filed_date":"2021-11-10","accession":"0001104659-21-137015","full_text":"https://origin.rootz.global/static/filing/0001104659-21-137015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":29,"match_count":3,"context":"Pro Forma Shares Outstanding 113.3 Post-Transaction Equity Value $1,133 (-Cash) (250) Pro Forma Enterprise Value $884 &#x25AA; OmniAb, Inc., an antibody discovery business wholly owned by Ligand, has entered into a definitive agreement to merge with Avista Public Acquisition Corp. II (APAC) (NASDAQ: AHPA), valuing OmniAb at a fully diluted pre- money equity valuation of $850 million - OmniAb to become an independent publicly traded","filed_date":"2022-03-23","accession":"0001104659-22-037111","full_text":"https://origin.rootz.global/static/filing/0001104659-22-037111.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":26,"match_count":2,"context":"arious legal proceedings arising in its ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on the condensed consolidated financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inhere","filed_date":"2025-11-04","accession":"0001628280-25-048923","full_text":"https://origin.rootz.global/static/filing/0001628280-25-048923.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":26,"match_count":2,"context":"arious legal proceedings arising in its ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on the condensed consolidated financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inhere","filed_date":"2025-08-06","accession":"0001846253-25-000066","full_text":"https://origin.rootz.global/static/filing/0001846253-25-000066.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":26,"match_count":2,"context":"arious legal proceedings arising in its ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on the condensed consolidated financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inhere","filed_date":"2025-05-08","accession":"0001846253-25-000055","full_text":"https://origin.rootz.global/static/filing/0001846253-25-000055.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":26,"match_count":2,"context":"arious legal proceedings arising in its ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on the condensed consolidated financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inhere","filed_date":"2024-11-12","accession":"0001846253-24-000088","full_text":"https://origin.rootz.global/static/filing/0001846253-24-000088.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":26,"match_count":2,"context":"arious legal proceedings arising in its ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on the condensed consolidated financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inhere","filed_date":"2024-08-08","accession":"0001846253-24-000073","full_text":"https://origin.rootz.global/static/filing/0001846253-24-000073.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":26,"match_count":2,"context":"arious legal proceedings arising in its ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on the condensed consolidated financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inhere","filed_date":"2024-05-09","accession":"0001846253-24-000034","full_text":"https://origin.rootz.global/static/filing/0001846253-24-000034.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":26,"match_count":2,"context":"arious legal proceedings arising in its ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on the condensed consolidated and combined financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of dispu","filed_date":"2023-11-09","accession":"0001846253-23-000120","full_text":"https://origin.rootz.global/static/filing/0001846253-23-000120.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":26,"match_count":2,"context":"arious legal proceedings arising in its ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on the condensed consolidated and combined financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of dispu","filed_date":"2023-08-10","accession":"0001846253-23-000096","full_text":"https://origin.rootz.global/static/filing/0001846253-23-000096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"risk_factor","strength":26,"match_count":2,"context":"arious legal proceedings arising in its ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on the condensed consolidated financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inhere","filed_date":"2026-08-06","accession":"0001846253-26-000046","full_text":"https://origin.rootz.global/static/filing/0001846253-26-000046.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"growth_inflection","strength":24,"match_count":3,"context":"| Royalty revenue | 1,367 | | | | | | 1,367 | | | NM(1) | | | Total revenue | $ | 59,077 | | | $ | 34,748 | | | $ | 24,329 | | | 70 | % | | _____________ (1)Percentage change is not meaningful. Total revenue increased $24.3 million, or 70%, in the year ended December31, 2022 as compared to 2021 driven primarily by (1) additional milestone revenue following the first commercial sale of teclistamab in the U.S. during the year end","filed_date":"2023-03-30","accession":"0001846253-23-000026","full_text":"https://origin.rootz.global/static/filing/0001846253-23-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":24,"match_count":3,"context":"orm licensing agreements with Dianthus Therapeutics, Hillstream Biopharma, NGM Bio, TriPhase Accelerator, and a stealth-mode biotech company focused on multi-specific antibodies. Additionally, OmniAb entered into a licensing agreement with Talem Therapeutics for three internally discovered antibody programs targeting B7-H3, CD38 and TIM3.  **Upcoming Conferences** OmniAb will be participating at the Stifel Healthcare Conference, N","filed_date":"2022-11-15","accession":"0001193125-22-285236","full_text":"https://origin.rootz.global/static/filing/0001193125-22-285236.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OABI","company":"OmniAb, Inc.","exchange":"Nasdaq","sector":"Services-Commercial Physical & Biological Research","signal_type":"strategic_event","strength":24,"match_count":3,"context":"rcise its warrants only for a whole number of Class A ordinary shares. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Accordingly, unless you purchase at least three units, you will not be able to receive or trade a whole warrant. The warrants will expire five yearsafter","filed_date":"2022-08-12","accession":"0001104659-22-089508","full_text":"https://origin.rootz.global/static/filing/0001104659-22-089508.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"f395799f35d4b181f3e69794c6d0512b3f26f784e8ff1d5f936e1081f606554a","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"f740710e0e1f5a86c354d3f61e3b3430514e34902ca126a999bf19a538febcbb","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":60,"hourly_limit":500,"remaining":440,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}